Physician profile
Sherly Abraham
NPI 1801008099
$1,887.96
in general payments reported to CMS, 2019-2025
24 companies · $116 in 2025
The $116 reported for 2025 was more than what a typical Hospice and Palliative Medicine (Family Medicine) provider received nationally (typical 2025 total: $78.57).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $436 · 2021: $274 · 2022: $227 · 2023: $152 · 2024: $183 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $450.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $289.89 | 2021-2025 | |
| Novo Nordisk INC | $277.08 | 2019-2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $201.49 | 2019-2021 | |
| Daiichi Sankyo INC. | $191.32 | 2019-2023 | Injectafer |
| Lilly USA, LLC | $158.53 | 2019-2022 | |
| Amgen INC. | $142.92 | 2019-2020 | |
| Pfizer INC. | $89.25 | 2019-2023 | |
| Amarin Pharma, INC. | $75.14 | 2020-2021 | |
| Glaxosmithkline, LLC. | $72.73 | 2023-2024 | Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.89 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.44 | 2020-2024 | Jardiance |
| Avion Pharmaceuticals | $39.22 | 2022 | |
| Merck Sharp & Dohme LLC | $32.29 | 2019-2022 | |
| Exact Sciences Corporation | $28.89 | 2024 | Cologuard Collection Kit |
| Allergan, INC. | $27.62 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $25.97 | 2024 | Percept PC Brainsense |
| Novartis Pharmaceuticals Corporation | $24.55 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.40 | 2024 | Eliquis |
| Ironwood Pharmaceuticals, INC | $21.67 | 2020 | |
| Phadia US INC. | $19.04 | 2019 | |
| Genentech USA, INC. | $17.71 | 2019 | |
| Currax Pharmaceuticals LLC | $15.70 | 2025 | Contrave |
| Teleflex LLC | $15.27 | 2021 | |
| Boston Scientific Corporation | $11.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherly Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.